Teclistamab (Tecvayli) is an off-the-shelf first-in-class bispecific monoclonal antibody shown in the MajesTEC-1 trial to ...

New research reveals teclistamab and daratumumab significantly enhance progression-free survival in multiple myeloma, ...

Expanding bispecific antibody access for multiple myeloma involves collaboration between academic centers and community ...

Wells Fargo just kicked off coverage on Arcellx (ACLX), zeroing in on its experimental CAR T therapy for multiple myeloma as a potential future treatment backbone and putting the company more firmly ...

Berenson Cancer Center published survival data analyzed by the Institute for Myeloma & Bone Cancer Research of 175 consecutive and unselected patients with multiple myeloma in the journal ...

No two cancers are the same. While most people know about cancer, when you get down to the disease level, each type is unique. Take blood cancers, for example: leukemia, lymphoma, and multiple myeloma ...

Lynozyfic (linvoseltamab-gcpt) is a prescription injection medicine for people with a type of blood cancer called multiple myeloma, whose cancer has come back (relapsed) or worsened (refractory) after ...

A four-drug regimen offers superior disease control and response depth in multiple myeloma compared to three-drug regimens. Adding monoclonal antibodies like Darzalex to standard treatments improves ...

How Does Darzalex Faspro Work for Multiple Myeloma? Darzalex Faspro is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by ...

Since the beginning of this century, advances in understanding the biology of multiple myeloma have transformed the disease from universally fatal to curable for a substantial proportion of patients.

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...